BRAF and metastatic melanoma: Furthermore, in 2020, a combination therapy consisting of the anti-PDL-1 antibody atezolizumab (branded as Tecentriq) along with the BRAF inhibitor vemurafenib (marketed as Zelboraf) and the MEK inhibitor cobimetinib (sold under the name Cotellic) received approval for the treatment of BRAF V600 mutation-positive unresectable or metastatic melanoma [7, 9, 13–17].